Home>>Signaling Pathways>> DNA Damage/DNA Repair>> Deubiquitinase>>FT671

FT671 Sale

目录号 : GC32786

FT671是一种是有效的选择性泛素特异性蛋白酶7(USP7)抑制剂,IC50值为52nM。

FT671 Chemical Structure

Cas No.:1959551-26-8

规格 价格 库存 购买数量
10mM (in 1mL DMSO)
¥3,010.00
现货
1mg
¥1,260.00
现货
5mg
¥2,565.00
现货
10mg
¥4,725.00
现货
25mg
¥10,125.00
现货
50mg
¥16,875.00
现货
100mg
¥26,325.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

Description

FT671 is a potent and selective inhibitor of ubiquitin-specific protease 7 (USP7) with an IC50 value of 52nM[1]. USP7 can deubiquitinate MDM2, resulting in a decrease in the intracellular level of p53[2]. FT671 has anti-tumor activity[3].

In vitro, pretreatment of A549 cells with FT671 (0-24µM) for 4h significantly promoted the degradation of intracellular SP1 and β-Catenin proteins[4]. Treatment of colorectal cancer HCT116 cells with FT671 (10µM) for 5min significantly attenuated intracellular protein ubiquitination under the condition of USP7 knockdown[5].

In vivo, oral treatment of MM.1S cell xenograft mice with FT671 (100, 200mg/kg) significantly inhibited the growth of tumors in mice in a dose-dependent manner and was well tolerated[6].

References:
[1] Tanguturi P, Kim K S, Ramakrishna S. The role of deubiquitinating enzymes in cancer drug resistance[J]. Cancer chemotherapy and pharmacology, 2020, 85(4): 627-639.
[2] Park H B, Baek K H. Current and future directions of USP7 interactome in cancer study[J]. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer, 2023, 1878(6): 188992.
[3] Cheng Y J, Zhuang Z, Miao Y L, et al. Identification of YCH2823 as a novel USP7 inhibitor for cancer therapy[J]. Biochemical Pharmacology, 2024, 222: 116071.
[4] Zhang K, Sun T, Li W, et al. Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells[J]. Cell Communication and Signaling, 2023, 21(1): 319.
[5] Steger M, Demichev V, Backman M, et al. Time-resolved in vivo ubiquitinome profiling by DIA-MS reveals USP7 targets on a proteome-wide scale[J]. Nature communications, 2021, 12(1): 5399.
[6] Turnbull A P, Ioannidis S, Krajewski W W, et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors[J]. Nature, 2017, 550(7677): 481-486.

FT671是一种是有效的选择性泛素特异性蛋白酶7(USP7)抑制剂,IC50值为52nM[1]。USP7能将MDM2去泛素化,从而导致p53的细胞内水平下降[2]。FT671具有抗肿瘤活性[3]

在体外,FT671(0-24µM)预处理A549细胞4h,显著促进了细胞内SP1和β-Catenin蛋白的降解[4]。FT671(10µM)处理结直肠癌HCT116细胞5min,在USP7敲低的条件下,显著减弱了细胞内蛋白质泛素化[5]

在体内,FT671(100, 200mg/kg)通过口服治疗MM.1S细胞异种移植小鼠,以剂量依赖性方式显著抑制了小鼠体内肿瘤的生长,并具有良好的耐受性[6]

实验参考方法

Cell experiment [1]:

Cell lines

A549 cells

Preparation Method

A549 cells were pretreated with FT671(0, 2, 4, 8, 16, 24µM) for 4h, and then treated with 50μg/mL cycloheximide (CHX) for 0-24h, and the protein was used for Western blot analysis.

Reaction Conditions

0, 2, 4, 8, 16, 24µM; 4h

Applications

FT671 significantly promoted the degradation of both SP1 and β-Catenin in A549 cancer cells.

Animal experiment [2]:

Animal models

Non-obese diabetic-severe combined immunodeficient (NOD-SCID) mice

Preparation Method

6 to 8-week-old female NOD SCID mice were irradiated (2Gγ) with a Co60 irradiator source 24h prior to subcutaneous inoculation of 5×106 MM.1S tumor cells in 1:1 mixture of RPMI-1640 and Matrigel. The efficacy study was initiated when tumors had reached an average volume of 159 mm3. Tumour-bearing mice were randomly assigned to treatment groups such that each treatment group had the same average tumor volume. Mice received a lead-in dose of 25mg/kg of FT671 24h prior to starting on the dosing regimen of 100 or 200mg/kg FT671 (once a day, per os by oral gavage). 10% DMA/90% PEG400 served as a vehicle control. For the statistical analysis of differences in tumor volumes between treatment groups, a 2-way ANOVA with repeated measures was performed followed by correction for multiple comparisons using statistical hypothesis testing (Tukey).

Dosage form

100, 200mg/kg/day; p.o.

Applications

Treatment of mice with FT671 led to significant dose-dependent tumor growth inhibition. FT671 was well tolerated even at high doses, and no significant weight loss or cachexia was observed during the study.

References:
[1]Zhang K, Sun T, Li W, et al. Inhibition of USP7 upregulates USP22 and activates its downstream cancer-related signaling pathways in human cancer cells[J]. Cell Communication and Signaling, 2023, 21(1): 319.
[2]Turnbull A P, Ioannidis S, Krajewski W W, et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors[J]. Nature, 2017, 550(7677): 481-486.

化学性质

Cas No. 1959551-26-8 SDF
Canonical SMILES FC1=CC=C(N2N=CC3=C2N=CN(CC4(O)CCN(C(C[C@@H](C(F)F)N5N=C(F)C=C5)=O)CC4)C3=O)C=C1
分子式 C24H23F4N7O3 分子量 533.48
溶解度 DMSO: 50 mg/mL (93.72 mM) 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 1.8745 mL 9.3724 mL 18.7448 mL
5 mM 0.3749 mL 1.8745 mL 3.749 mL
10 mM 0.1874 mL 0.9372 mL 1.8745 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

产品文档

Quality Control & SDS

View current batch: